Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 11/20 | 0.52 |
| ▸ | HTR1A | P08908 | 10/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.46 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.46 |
| ▸ | GLRB | P48167 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | SMO | Q99835 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4366101 | 0.80 | ALDH1A1 (0.46) | PDE4DPDE4APDE4BPDE4C | |
| Hydrochloric Acid SCHEMBL1134115 | 0.79 | PDE4A (0.45) | SLC6A2HTR1ASLC6A4PDE4DPDE4A | |
| SCHEMBL7360412 | 0.77 | TAAR1 (0.53) | — | |
| SCHEMBL636344 | 0.76 | SRC (0.52) | PDE4DPDE4APDE4BPDE4C | |
| Hydrochloric Acid SCHEMBL7360764 | 0.76 | TAAR1 (0.51) | — | |
| SCHEMBL16334980 | 0.76 | SLC6A2 (0.44) | SLC6A2HTR1ASLC6A3SLC6A4 | |
| SCHEMBL1627720 | 0.76 | NFE2L2 (0.50) | — | |
| SCHEMBL29669870 | 0.76 | NFE2L2 (0.50) | — | |
| SCHEMBL28333005 | 0.75 | AXL (0.43) | SLC6A2HTR1ASLC6A3SLC6A4PDE4D | |
| SCHEMBL28757966 | 0.75 | KMT2A (0.44) | HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1692109-B1 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS | MEMORY PHARM CORP (US) | 2010-08-18 | — | — | EP | disclosed |
| CN-1922144-A | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs | MEMORY PHARM CORP (US) | 2007-02-28 | — | — | CN | disclosed |
| US-20050222207-A1 | Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs | MEMORY PHARMACEUTICAL CORPORATION | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222207-A1 | Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs | PDE4A, PDE4B, PDE3B | SLC6A2 1346/4885HTR1A 1128/4885SLC6A3 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.